Idorsia Ltd
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| IDIA.SW | HRMY | CRVS | ZVRA | IVA | IDYA | |
|---|---|---|---|---|---|---|
| Market cap | 1.24B | 2.22B | 876.12M | 600.96M | 872.84M | 3.28B |
| P/E (TTM) | — | 12.3 | — | 11.0 | — | — |
| Forward P/E | 83.0 | 5.4 | -9.8 | 9.4 | -5.0 | -8.3 |
| Price/book | -1.0 | 2.2 | 3.9 | 2.8 | 13.2 | 2.7 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +34.87% | +29.43% | +37.24% | −0.64% | −11.42% | +4.10% |
| Today | +0.88% | +0.45% | −1.19% | +0.65% | +0.27% | +1.45% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All IDIA.SW news ›Idorsia seeks US label update for QUVIVIQ daytime functioning benefits – first patients enrolled in Dari-Dream
Building on established clinical evidence, Dari-Dream is designed to further characterize the impact of QUVIVIQ on daytime functioning and support its inclusion in the US prescribing information. Allschwil, Switzerland – October 27,…
A new scientific avenue for daridorexant: Idorsia to advance development in autism spectrum disorder
In a Phase 2 study in pediatric insomnia disorder, in addition to marked improvements in sleep measures, daridorexant 50 mg showed an unexpected pattern of improvement in affect and behavior, cognition, and daily activities in participants…
Idorsia presents outstanding results with daridorexant in children and adolescents with insomnia and an expanding body of evidence in adults at Sleep Europe 2026
Daridorexant, a dual orexin receptor antagonist, is the first investigational treatment in its class to demonstrate positive results in pediatric insomnia disorder, an area in which significant unmet needs remain for children and their…
New mouse tool targets microvascular endothelial cells in muscle and fat
Scientists have created a CTRP9-CreERT2 knock-in mouse line whose tamoxifen-inducible reporter selectively labels microvascular endothelial cells in heart, skeletal muscle, tongue and adipose tissue. Researchers have built a genetically…
Idorsia | Presentation of the Phase 2 results of daridorexant in pediatric insomnia
+41 58 844 00 00 Please get in touch with us via the contact form by clicking "Next". Learn more about our Governance by clicking "Next" Idorsia attempts to ensure that your Personal Data are updated, accurate, and complete according to…
Idorsia Ltd Presents Phase 2 Results With Daridorexant In Children With Insomnia Disorder And Adult Evidence At Sleep Europe 2026
Idorsia Ltd. announced results from the first and only Phase 2 study with a dual orexin receptor antagonist in children with insomnia disorder, presented to the scientific community at Sleep Europe ...
Idorsia Ltd Announces New Results Across Pediatric, Adult and Real-World Insomnia Settings Highlight the Expanding Clinical Evidence for Daridorexant At Sleep Europe 2026
Idorsia Ltd. continued its commitment to advancing the science of sleep and insomnia at Sleep Europe 2026, taking place in Maastricht, the Netherlands, from October 20 to 23, 2026. The scientific...
After tax other income/expense of Idorsia Ltd. – XETR:19T
TradingView After tax other income/expense of Idorsia Ltd.
Blood Pressure Drug Losartan May Boost Brown Fat Activity And Improve Metabolism, Study Finds
A commonly prescribed blood pressure drug could offer a new way to improve the body’s metabolism by activating brown fat, a type of tissue that burns energy to produce heat, according to a U.S. government-funded study. Researchers found…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com17
- tradingview.com3
- idorsia.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 21 articles, not a forecast.